Decibel Therapeutics is a technology company.
Decibel Therapeutics has raised $189.0M across 3 funding rounds.
Decibel Therapeutics has raised $189.0M in total across 3 funding rounds.
Decibel Therapeutics is a clinical-stage biotechnology company developing gene therapies to protect, repair, and restore hearing and balance, targeting profound congenital hearing loss caused by genetic mutations like OTOF deficiency[1][2][3][4][5]. Its lead product candidate, DB-OTO, is an AAV-based dual-vector gene therapy designed to deliver functional otoferlin to inner hair cells, enabling sound signal transmission to the brain and providing durable hearing restoration for children[2][3][5]. The company serves pediatric patients and families affected by monogenic hearing loss, addressing a critical unmet need where current treatments like cochlear implants offer only partial solutions, through initiatives like the Amplify genetic testing program and patient education[2]. Growth momentum includes launching the CHORD Phase 1/2 clinical trial in May 2023 across the US, UK, and Spain, plus Orphan Drug Designations from FDA and EMA[3].
Founded in 2015 by Third Rock Ventures and headquartered in Cambridge, Massachusetts, Decibel Therapeutics emerged from innovations in hearing science, genetics, and drug delivery, led by preeminent experts in impaired hearing[1]. The company assembled a world-class scientific advisory board in 2016, featuring leaders in neuroscience, genetics, and drug discovery to guide its pioneering approach[1]. Key early traction came from developing DB-OTO for OTOF-mediated hearing loss and launching patient-focused programs like Amplify to identify genetic causes and build advocacy[2].
Decibel rides the wave of gene therapy advancements for monogenic diseases, leveraging AAV vectors amid rising success in rare disorders like spinal muscular atrophy and hemophilia[3]. Timing aligns with expanded genetic testing accessibility and regulatory support for orphan indications, amplified by post-pandemic focus on pediatric unmet needs[2][3]. Market forces favoring Decibel include a 466 million global hearing loss cases (projected to double by 2050 per WHO estimates, though not directly cited here) and biotech investor interest in precision medicine[1][4]. It influences the ecosystem by advancing genetic diagnostics integration into audiology, potentially shifting standards from implants to curative therapies[2][3].
Decibel's CHORD trial data readouts could validate DB-OTO as a first-in-class therapy, paving for expanded indications in other genetic hearing losses and balance disorders[3][4]. Trends like AI-driven diagnostics and next-gen AAV capsids will accelerate its pipeline, while partnerships (e.g., Regeneron) bolster scalability[3]. Influence may evolve from niche innovator to ecosystem leader, unlocking hearing restoration and redefining biotech's impact on sensory disorders—transforming lives muted by genetics, much like its mission to deliver durable hearing where none existed[1][5].
Decibel Therapeutics has raised $189.0M in total across 3 funding rounds.
Decibel Therapeutics's investors include GV, The Column Group, Versant Ventures, Apollo Health Ventures, LearnLaunch Accelerator, Qiming Venture Partners USA, Wayne Chang.
Decibel Therapeutics has raised $189.0M across 3 funding rounds. Most recently, it raised $82.0M Series D in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $82.0M Series D | GV, The Column Group, Versant Ventures | |
| Jun 1, 2018 | $55.0M Series C | Apollo Health Ventures, GV, LearnLaunch Accelerator, Qiming Venture Partners USA, The Column Group, Versant Ventures, Wayne Chang | |
| Oct 1, 2015 | $52.0M Series A | Apollo Health Ventures, LearnLaunch Accelerator, Qiming Venture Partners USA, Wayne Chang |